Navigation Links
Synta Pharmaceuticals to Host Conference Call Today

LEXINGTON, Mass.--(BUSINESS WIRE)--Jun 5, 2007 - Synta Pharmaceuticals Corp., (NASDAQ: SNTA) a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced it will hold a conference call at 2:30 p.m. (EST) today to discuss these results, which will be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois this morning.

The conference call will be webcast live over the Internet. The webcast can be accessed by logging on to the "Investors" section of Synta Pharmaceuticals' website, www.syntapharma.com, prior to the event.

The call also can be accessed by dialing (877) 407-8035 or (201) 689-8035 prior to the start of the call. The webcast will be archived on the Company's website.

About Synta Pharmaceuticals

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were discovered and developed internally. For more information, please see www.syntapharma.com

Contact

Synta Pharmaceuticals Corp.
Rob Kloppenburg, 781-541-7125
or
MacDougall Biomedical Communications
Doug MacDougall, 508-647-0209


'"/>




Page: 1

Related medicine technology :

1. Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival
2. Synta Oncology Candidate STA-4783 Clinical Trial Results to Be Presented at the ASCO Annual Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... SAO PAULO , March 23, 2017 ... accordance with article 157, paragraph 4 of Law 6,404/76 ... Commission (CVM), hereby informs its shareholders and the market ... jointly with its subsidiary Centro de Diagnosticos por Imagem ... acquisition of 100% interest in RADIOLOGISTAS ASSOCIADOS LTDA. (" ...
(Date:3/23/2017)... , March 23, 2017 Ascendis Pharma ... innovative TransCon technology to address significant unmet medical needs ... host a conference call and webcast on Monday, April ... Endocrine Society in Orlando, Florida , ... pipeline candidates (TransCon Growth Hormone, TransCon PTH and TransCon ...
(Date:3/23/2017)... , March 23, 2017 /PRNewswire/ - INVICTUS MD STRATEGIES ... FRA: 8IS) Invictus MD announces that AB Laboratories Inc. ... its licensed production facility under the Access to Cannabis ... Hamilton, Ontario . The facility, ... October 2016, is currently operating at half capacity, with ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... 82% of adults are unaware of the dangers that ... brush their teeth the minimum two times a day that dentists recommend. The ramifications of ... million hours of school and adults missing 164 million hours of work each year due ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... Accreditation from the NCQA. The accreditation covers StayWell’s asthma, coronary artery disease, congestive ... is granted to organizations that have excellent programs for the delivery and improvement ...
(Date:3/23/2017)... ... 23, 2017 , ... Michael Lanteri Agency, an insurance and ... area, has unveiled a collaboration with nonprofit Big Bones Canine Rescue as the ... cause may now be made at http://bigbonescaninerescue.com/ . , Big Bones Canine ...
(Date:3/23/2017)... ... March 23, 2017 , ... ?This conference will prominently feature 150+ Hospital and Health System ... AMN Healthcare: Susan Salka , 43rd President of the United States of America: ... My Life In and Out of the Ring: Sugar Ray Leonard , JD, ...
(Date:3/23/2017)... ... March 23, 2017 , ... Natural Subsistence, a company known ... health and nutrition, announced its product Leyzene is now available for purchase on ... supplements that help people improve all aspects of their health so they can ...
Breaking Medicine News(10 mins):